The Substance Abuse and Mental Health Services Administration (SAMHSA) estimated that in 2012 there were 467,000 people who abused or were dependent on heroin; the prevalence of past month non-medical use of pain relievers was 1.9% (SAMSHA, 2013). In fact, these figures probably vastly underestimate the true prevalence of opioid use disorders in the United States (SAMHSA, 2005). Further, only a small fraction of these users have received treatment for an opioid use disorder (SAMHSA, 2005).
Buprenorphine is a safe and effective treatment for opioid dependence that offers patients a more widely available, accessible, convenient treatment option as compared to traditional opioid treatment programs (OTP) (SAMHSA, 2001; Johnson et al., 2003; SAMHSA, 2004). The Drug Addiction Treatment Act (DATA) of 2000 -- an amendment to the Controlled Substances Act -- allows physicians who are not part of an OTP to prescribe buprenorphine. However, the law requires physicians to complete an 8-hour buprenorphine training conducted by an approved organization in order to prescribe it.
This buprenorphine training program prepares physicians to prescribe buprenorphine safely and effectively to address needs of the millions of Americans with opioid use problems. In addition, the program has been developed to meet the DATA 2000 training guidelines as defined in Public Law 106-310-106th Congress and is endorsed by the American Society of Addiction Medicine, one of the approved training organizations named in DATA 2000. The program content is based upon SAMHSA’s 2004 publication Treatment Improvement Protocol (TIP) #40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. The courses are regularly reviewed and updated by ASAM members who are experts in the field of addiction medicine and buprenorphine treatment.
Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(suppl 2): S59-S77. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12738351.
Substance Abuse and Mental Health Services Administration (SAMHSA). Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. Substance Abuse and Mental Health Services Administration. 2001. Available at: http://www.buprenorphine.samhsa.gov/Buprenorphine_Curriculum.pdf.
Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, Md: Center For Substance Abuse Treatment. Treatment Improvement Protocol Series, No. 40, USDHHS Publication (SMA) 04-3939. 2004b. Available at: http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf.
Substance Abuse and Mental Health Services Administration (SAMHSA). Overview of Findings From the 2004 National Survey on Drug Use and Health. Rockville, Md: Office of Applied Studies. 2005. Available at: http://oas.samhsa.gov/NSDUH/2k4NSDUH/2k4Overview/2k4Overview.pdf.
Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, Md: Office of Applied Studies. 2013. Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm#ch2
This program is designed to change: Competence, Performance, Patient Outcome.
Expand your practice to comply with the regulations and requirements of office based buprenorphine treatment
Relate buprenorphine's pharmacological properties to its drug effects and understand the physiological effects of opioids and opioid treatments on patients
Identify, assess, and diagnose opioid use and dependence in your patients
Utilize medical and substance abuse history information to assess your patients in terms of suitability of treatment with buprenorphine
Provide effective and successful treatment to your patients throughout the phases of buprenorphine treatment: induction, maintenance, and discontinuation, and deal with complications that arise
Assess and adapt treatment guidelines to best treat your patients from specific patient populations, including those with psychiatric comorbidities, adolescents, the elderly, pregnant women, methadone transfers, and patients with pain
Prescribe, refer, or implement appropriate psychosocial therapies for treating opioid dependence
Program Activity Syllabus
Audience and Accreditation
|Type: AMA PRA Category 1 Credit(s)™||Est. Time: 9 hr(s)||Released: 10/1/11||Expires: 10/23/13|
Credit Statement for AMA PRA Category 1 Credit(s)™: Clinical Tools, Inc. designates this enduring material for a maximum of 9 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- A letter of completion for up to 9 hour(s) is available for non-physicians.
A score of 70% on the post-test is required to complete the program.
Program Credit: Obtaining credit for participation in this program requires that you complete the pre-assessments, work through the modules (including all in-module interactive activities), complete the post-assessments with a 70% score on the post-test, and then request credit. At the end of the program, you will be instructed on how to print out a certificate for your records.
Time Requirement: Keep track of the amount of time it takes you to complete this program. You will be required to spend a set amount of time in order to claim credit. You should claim credit only for the time actually spent in the activity.
Technical Requirements: To participate in this program, you will need a computer, an Internet connection, and a Web browser. This program requires Chrome, Firefox, and IE7 or higher.